A Study on the Effectiveness of Mono and Dual Antiplatelet Therapy in Secondary Prevention of Vascular Events

The aim of the study was to determine whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in the prevention of secondary vascular events in patients after TIA or ischemic stroke. Out of the total patients, 34.2 % of patients had recurrence of vascular events. 36.3 % patients reached the primary endpoint in the group receiving dual therapy compared to 20% in the monotherapy group. 31% in dual therapy group had Ischemic stroke as qualifying event compared to 5 % in monotherapy. Our study focused on the prevalence of risk factors in patients with recurrence of vascular events. Risk factors found were previous ischemic stroke in 12 % of dual therapy group and 1% in mono group. Hypertension was found in 30 % of dual group and 3 % of mono group. Diabetes was risk factor in 16% of dual therapy patients and 4% in mono group Hypercholesterolemia was found in 19% of dual group and 4 % of mono group11% of dual therapy patients and 2 % of mono therapy patients were smokers. The primary events were found to have a significant association with gender, risk factors and therapy. No bleeding complications were observed in the study population.